MediCor's Eurosilicone Subsidiary's Breast Implants Approved for Sale in Australia; Company Chosen Number One in the PACA Region of France.

LAS VEGAS -- MediCor Ltd. (OTCBB:MDCR), a global integrator of medical device companies and the world's third largest manufacturer of breast implants, announced today its wholly-owned subsidiary Laboratoires Eurosilicone, S.A. ("Eurosilicone") has been granted authorization to market its Cristalline Paragel breast implant products in Australia.

The Australian Government's Therapeutic Goods Administration ("TGA") approval of the Cristalline Paragel breast implant product line is the result of a two-year collaborative effort led by the Tourniaire family between the TGA, Eurosilicone, and its Australian distribution partner, Technology For Life Pty. Ltd., Australia's largest distributor of aesthetic, plastic and reconstructive surgical devices.

"The highly anticipated approval of the Cristalline Paragel product line is being well received by the aesthetic plastic and reconstructive surgery community in Australia," according to David G. Barella, MediCor Executive Vice President of International Marketing and Sales, who added, "Approximately 85% of all implants sold in Australia are textured round implants, and the Cristalline Paragel offers surgeons and patients an array of significant product improvements over other currently available textured round implants. The entry into the Australian market is another of the numerous steps MediCor has underway to become the preeminent company in the worldwide breast implant market."

In a separate, but related announcement, Eurosilicone has been awarded the distinction of being the number one company in the PACA region (Provence - Alpes - Cotes d'Azur) of France. The prestigious award is the result of a collaborative effort between COFACE, a public organization associated with the French Government, FIGARO, a major French newspaper, and France Bleu radio, all of whom collectively worked to analyze and review hundreds of companies in the region. Eurosilicone was chosen for its exemplary performance based upon a comprehensive list of evaluation criteria, including sales growth, profitability, its percentage of exports and employee hiring rates. Francois Tourniaire, Eurosilicone's President Directuer Generale, graciously accepted the award on behalf of the company's 190 employees and strategic partners, and stated, "Our employees and distribution partners earned this award through their unwavering commitment to the highest levels of quality and customer satisfaction."

MediCor also announced today that Patrick O'Leary, Ph.D. has accepted to the position of Director Generale Delegue for Eurosilicone. Dr. O'Leary has more than 25 years senior management experience in the medical device sector, including having served as President of Eurosilicone's main competitor, Inamed-Europe and its subsidiary, McGhan Ltd. O'Leary is considered an industry leader and has a significant background in building and operating U.S. Food and Drug Administration ("FDA") approved medical device manufacturing facilities, both domestically and abroad.

About Eurosilicone

Eurosilicone, a wholly-owned subsidiary of MediCor Ltd., develops, manufactures and markets a full range of breast implants for the aesthetic, plastic and reconstructive surgery markets, including silicone gel and inflatable saline-filled breast implants, with both round and anatomical shapes, and smooth or unique micro-textured surfaces. Eurosilicone also markets a line of external breast prostheses under the Maxima brand sold by its Europrotex division, available in six different shapes and a wide range of sizes. Eurosilicone also manufactures and markets a range of other silicone implants, including tissue expanders, testicular implants, gluteus implants, calf implants, nasal implants, malar implants and chin implants.

About MediCor

MediCor acquires, develops, manufactures and markets products for medical specialties in aesthetic, plastic and reconstructive surgery and dermatology markets. Its products are sold worldwide to hospitals, surgery centers and physicians through a combination of distributors and direct sales personnel. MediCor's strategy is to be the leading integrator of selected international medical device markets, technologies and corporations. MediCor intends to accomplish this growth through the expansion of existing product lines, as well as the acquisition of companies and other assets, including intellectual property rights or distribution rights.

Forward Looking Statements

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of MediCor's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

Factors that could cause MediCor's results to differ materially from those described in the forward-looking statements can be found in the 2003 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB of MediCor filed with the Securities and Exchange Commission and available at the Securities and Exchange commission's Internet site (http://www.sec.gov).